Ketek
(telithromycin)ApprovedSmall molecule
SanofiTelithromycin is an antibiotic used to treat bacterial infections, particularly respiratory tract infections like community-acquired pneumonia and bronchitis.[2] Ketek is currently approved and in use across 15 indications[4].[1]
Ketek is one of 252 small molecule programs targeting Scrub Typhus. It is currently in Approved.
15
Indications
22
Total Trials
0
Active Trials
251
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 15 indications
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Ketek
SanofiApproved
Veramyst
GSKPreclinical
Nucala
GGlaxo Dba Glaxosmithkline
Preclinical
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Asmanex
NovartisPreclinical
Atrovent
Boehringer IngelheimPreclinical
Formoterol Fumarate
AstraZenecaPreclinical
Atrovent
Boehringer IngelheimPreclinical
Aciphex
Akero TherapeuticsPreclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Pneumonia3 trials
Respiratory tract infection3 trials
Chronic Bronchitis3 trials
Sinusitis2 trials
9 more indications
Efficacy and Safety1 trial
Acute otitis media1 trial
Acceptability1 trial
Scrub Typhus1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Feb 9, 2005
KETEK
NDA NDA021144
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Ketek drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for telithromycin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]